ASCO 2022 Conference Coverage


 

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC

238 views
June 23, 2022
Comments 0
Login to view comments. Click here to Login